Concepedia

Karen H. Antman

KH

102

Publications

9.1K

Citations

53

H-Index

1979

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Columbia University

Brigham and Women's Hospital

Boston University

Karen H. Antman is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pathology.

Top concepts

Publications per year

1979–2018

102

Publications

102

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

Karen H. Antman, John Crowley, S P Balcerzak et al. · Journal of Clinical Oncology · 1993 · 477 citations

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.

T. Frank, Susan Manley, O. I. Olopade et al. · Journal of Clinical Oncology · 1998 · 462 citations

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.

Lee M. Nadler, Philip Stashenko, Russell Hardy et al. · PubMed · 1980 · 416 citations

, , +17

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

Karen H. Antman, Lois Ayash, Anthony Elias et al. · Journal of Clinical Oncology · 1992 · 374 citations

Introduction: The History of Arsenic Trioxide in Cancer Therapy

Karen H. Antman · The Oncologist · 2001 · 358 citations · Full text

, , +17

Rows per page

1–5 of 102